Aranesp® (darbepoetin alfa) |
||
| Aranesp® is indicated for the treatment of anemia associated with chronic renal failure (both in patients on dialysis and those not on dialysis), as well as for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies. It was approved in 2001 for patients with chronic renal failure, and in 2002 for the treatment of chemotherapy-induced anemia. |
||
Aranesp® SureClick™ (darbepoetin alfa) |
||
| Especially for injecting subcutaneously (SC) Aranesp, (see link below for more information about this product), is prescribed as a ready to use, self administration device Aranesp SureClick. Aranesp SureClick simplifies the administration of Aranesp for patients. Aranesp SureClick is available in preset dosages for single use.
Aranesp SureClick is available in the Netherlands since September 1, 2005. |
||
Aranesp® prefilled syringe with Automatic Needle Guard (darbepoetin alfa) |
||
| Amgen continuously improves its products and injection methods in terms of safety and patient convenience. After introducing Aranesp SureClick in 2005, Amgen also equipped the Aranesp prefilled syringe in 2009 with an Automatic Needle Guard, to prevent needle stick injuries. Both injection methods of Aranesp are now optimally equipped for safe administration of the product.
Aranesp prefilled syringe with Automatic Needle Guard is available since October 1st, 2009.
|
||
Mimpara® (cinacalcet HCl) |
||
| Mimpara® is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as the treatment of hypercalcemia in patients with parathyroid carcinoma. It was approved by the FDA and EMEA in 2004.
Mimpara is, since June 2008, also indicated for the treatment of primary HPT in patients were parathyrodectomy is indicated based on the serum calcium values (determined by the relevant treatment guidelines) but were parathyroïdectomy clinically not possible is or contraindicated. |
||
Neulasta® prefilled syringe with Automatic Needle Guard |
||
| Neulasta® is indicated for reducing the incidence of infection associated with chemotherapy-induced neutropenia in cancer patients with nonmyeloid malignancies. It was approved by the FDA and EMEA in 2002.
Amgen continues to improve its products by increasing safety precautions and making them user friendly. Since the introduction of Neulasta in 2003, Amgen increased safety with the introduction in 2010 of the Neulasta prefilled syringe with an Automatic Needle Guard. This prefilled syringe is now fully equipped for a safe administration of injections.
Neulasta prefilled syringe with Automatic Needle Guard is available since 1 June 2010 |
||
Neupogen® (Filgrastim) |
||
| Neupogen® is indicated for reducing the incidence of infection from chemotherapy-induced neutropenia in cancer patients with nonmyeloid malignancies. It was approved by the FDA for this indication in 1991. It is also indicated for patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, cancer patients receiving bone marrow transplant, patients undergoing peripheral blood progenitor cell collection and therapy, and patients with severe chronic neutropenia. |
||
Nplate® (romiplostim) |
||
| Nplate is indicated for adult patients with chronic immuun (idiopathic) thrombocytopenic purpura (ITP) who experienced a splenectomy and who are refractory to other treatments (for example corticosteroïds, immunoglobulins).
Nplate can be considered as second line treatment for adult, non -splenectomised ITP patients where surgery is contraindicated. Nplate is available in the Netherlands since August, 2009 |
||
Prolia® (denosumab) |
||
| Prolia® is used to treat osteoporosis (brittle bones) in women after menopause (postmenopausal), reducing the risk of a fracture (broken bone) of a vertebral, hip or another bone.
In addition, this medicine can be prescribed to prevent bone loss and reduce risk of fractures to cancer patients who are treated with hormone ablation therapy. In men with prostate cancer, socalled ‘androgeen deprivation therapy, i.e. chemical (with medicines) or surgical castration. In women with breast cancer this is going about the treatment with a aromatase inhibitor supplemental to the operation. The active substance of Prolia is denosumab that the action of a protein (RANK ligand) inhibits. The purpose of treatment is to reduce the risk of fractures by preventing bone loss and by treating osteoporosis.
Prolia is available in the Netherlands since March 2011 and is fully reimbursed. Message leave amgen |
||
Vectibix® (panitumumab) |
||
| Cancer in the large intestines including the rectum (colorectal cancer) which has spread through the body (metastasised) is commonly treated with chemotherapy (medicines used to treat cancer). However, it is possible that chemotherapy treatment may not be successful or after a certain treatment time the chemotherapy fails to work. At this stage one can start to try and treat the tumour with medication which will block the activation of the Epidermal Growth Factor Receptor (EGFR). Vectibix is such a medicine.
EGFR is expressed on metastatic colorectal cells. Once activated the EGFR promotes cell growth and the tumour grows and spreads.. Vectibix is an EGFR inhibitor which binds to the EGFR and blocks the activation. Binding of Vectibix to EGFR results in inhibition of cell growth and induction of cell death (apoptosis). KRAS is a protein that is involved in passing through a signal for cell growth when the EGFR is activated. If this protein is altered (mutated) in a particular tumour the signal will be passed through even if EGFR is blocked by Vectibix. Patients with normal acting (wild-type) KRAS who have failed to respond to their chemotherapy may profit from being treated with Vectibix. Vectibix is indicated for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC):
Vectibix contains the active substance panitumumab, which belongs to a group of medicines which are called monoclonal antibodies. Monoclonal antibodies are proteins, which specifically recognise and bind other proteins in the human body. Panitumumab recognises and binds EGFR. Panitumumab is the first fully human monoclonal antibody against EGFR. Vectibix is available since 2008 |
||
XGEVA® (denosumab) |
||
| XGEVA is prescribed to prevent skeletal related events in adult cancer patients with a solid tumor that has spread to the bone (bone metastases). These events include radiation to the bone because of pain or to prevent a fracture, fractures at the site of a bone metastasis, surgery to the bone to prevent a fracture, and spinal cord compression when the tumor or a part of a vertebra compresses the spinal cord.
The active substance in XGEVA is denosumab, which inhibits the activity of a protein (RANK Ligand) that stimulates bone resorption. The treatment goal is to delay the occurrence of skeletal related events by reducing bone destruction. XGEVA (120 mg denosumab) is given once every 4 weeks as a single subcutaneous (under the skin) injection in the thigh, abdomen or upper arm.
As of March 2012, XGEVA is available and fully reimbursed in the Netherlands. |
||
